In compliance with Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Board of Directors ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Lactose (India) Ltd's board approved unaudited Q3 FY26 results on Feb 13, 2026, accompanied by a clean (unqualified) limited review report from statutory auditor D M K H & Co. Q3 revenue from operations grew ~28% YoY to Rs. 3,676.71 lakhs, while Q3 PAT jumped ~142% to Rs. 52.84 lakhs, but this was on a very low base (Rs. 21.85 lakhs in Q3 FY25). For the nine-month period, revenue grew a stronger 32.6% YoY to Rs. 11,752.40 lakhs, yet 9M PAT actually fell 7.4% to Rs. 418.59 lakhs, signalling cost pressure as input, manufacturing and other expenses rose faster than sales. The company operates in a single Pharmaceuticals segment, reported no exceptional items, and the merger with Vitanosh Ingredients Pvt Ltd is awaiting NCLT approval after BSE issued its NOC in August 2025.
The Q3 profit jump looks dramatic but is flattered by a low base; the 9M numbers show revenue growth is not flowing through to bottom-line, indicating margin compression. Investors should track whether margins stabilise in Q4 and watch NCLT progress on the proposed Vitanosh merger for a potential re-rating catalyst.